Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells

Cell Cycle

Volumn 7, Issue 5, 2008, Pages 631-636

  Lee, John T ^a   Steelman, Linda S ^a   Chappell, William H ^a   McCubrey, James A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Akt; Prostate cancer; PTEN; Raf

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAF PROTEIN; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; PROSTATE CARCINOMA; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 41849083428     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.5.5416     Document Type: Article

References (59)

1. Gulley J, Dahut WL. Chemotherapy for prostate cancer: finally an advance! Am J Ther 2004; 11:288-94.
2. Gulley J, Dahut W. Novel clinical trials in androgen-independent prostate cancer. Clin Prostate Cancer 2002; 1:51-7.
3. Retter AS, Gulley JL, Dahut WL. Novel therapeutic strategies in prostate cancer. Cancer Biol Ther 2004; 3:371-6.
4. Comstock CES, Knudsen KE. The complex role of AR Signaling after cytotoxic insult: implications for cell cycle-based chemotherapeutics. Cell Cycle 2007; 6:1307-13.
5. Vander Griend DJ, Litvinov IV, Isaacs JT. Stablizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle 2007; 6:647-51.
6. Harris KA, Reese DM. Treatment options in hormone-refractory prostate cancer: current and future approaches. Drugs 2001; 61:2177-92.
7. Kruh GD. Introduction to resistance to anticancer agents. Oncogene 2003; 22:7262-4.
8. Garcia R, Franklin RA, McCubrey JA. EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle 2006; 5:2820-6.
9. Garcia R, Franklin RA, McCubrey JA. Cell death of MCF-7 human breast cancer cells induced by EGFR activation in the absence of other growth factors. Cell Cycle 2006; 5:1840-6.
10. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002; 62:6141-5.
11. Pfeil K, Eder IE, Putz T, et al. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate 2004; 58:259-68.
12. Lee JT Jr, Steelman LS, McCubrey JA. Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 2004; 64:8397-404.
13. Lee C, Kim JS, Waldman T. Activated PI3K signalling as an endogenous inducer of p53 in human cancer. Cell Cycle 2007; 6:394-6.
14. Skladanowski A, Bozko P, Sabisz M, Larsen AK. Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy. Cell Cycle 2007; 6:2268-75.
15. Shukla S, Gupta S. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle 2007; 6:1102-14.
16. Liu Z, Roberts TM. Human tumor mutants in the p110alpha subunit of PI3K. Cell Cycle 2006; 5:675-7.
17. Yoeli-Lerner M, Toker A. Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 2006; 5:603-5.
18. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002; 5:234-48.
19. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4:257-62.
20. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004;15:177-82.
21. Steelman LS, Bertrand FE, McCubrey JA. The complexity of PTEN: Mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets 2004; 8:537-50.
22. Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM, Manzoli L, McCubrey JA, Cocco L. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 2007; 14:2009-23.
23. Ittmann MM. Chromosome 10 alterations in prostate adenocarcinoma (review). Oncol Rep 1998; 5:1329-35.
24. Pesche S, Latil A, Muzeau F, Cussenot O, Fournier G, Longy M, Eng C, Lidereau R. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene, 1998; 16:2879-83.
25. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000; 14:2410-34.
26. Lee JT Jr, McCubrey JA. Targeting the Raf kinase cascade in cancer therapy - novel molecular targets and therapeutic strategies. Expert Opin Ther Targets 2002; 6:659-78.
27. Lee JT Jr, McCubrey JA. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 2002; 16:486-507.
28. Dhillon AS, von Kriegsheim A, Grindlay J, Kolch W. Phosphatase and feedback regulation of Raf-1 signaling. Cell Cycle 2007; 6:3-7.
29. Galabova Kovacs G, Kolbus A, Matzen D, Meissi K, Plazzolla D, Rubiolo C, Steinitz K, Baccarini M. ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts. Cell Cycle 2006; 5:1514-8.
30. Yeh PY, Chuang SE, Yeh KH, Song YC, Chang LL, Cheng AL. Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. Oncogene 2004; 23:3580-8.
31. Schweyer S, Soruri A, Meschter O, Heintze A, Zschunke F, Miosge N, Thelen P, Schlott T, Radzun HJ, Fayyazi A. Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation. Br J Cancer 2004; 91:589-98.
32. Xiao D, Singh SV. Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res 2002; 62:3615-9.
33. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto Ishida E, Nakatsuji Y, Tasaka K, Murata Y. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 2002; 277:33490-500.
34. Hatakeyama M, Kimura S, Naka T, Kawasaki T, Yumoto N, Ichikawa M, Kim JH, Saito K, Saeki M, Shirouzu M, Yokoyama S, Konagaya A. A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling. Biochem J 2003; 373:451-63.
35. Wang Z, Wang M, Carr BI. Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway. J Cell Physiol 2005; 203:510-9.
36. McCubrey JA, Steelman LS, Hoyle PE, Blalock WL, Weinstein-Oppenheimer C, Franklin RA, Cherwinski H, Bosch E, McMahon M. Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 1998; 12:1903-29.
37. Hoyle PE, Moye PW, Steelman LS, Blalock WL, Franklin RA, Pearce M, Cherwinski H, Bosch E, McMahon M, McCubrey JA. Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia 2000; 14:642-56.
38. Moye PW, Blalock WL, Hoyle PE, Chang F, Franklin RA, Weinstein- Oppenheimer C, Pearce M, Steelman L, McMahon M, McCubrey JA. Synergy between Raf and BCL2 in abrogating the cytokine dependency of hematopoietic cells. Leukemia 2000; 14:1060-79.
39. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999; 286:1741-4.
40. Rommel C, Clarke BA, Zimmermann S, Nuñez L, Rossman R, Reid K, Moelling K, Yancopoulos GD, Glass DJ. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999; 286:1738-41.
41. Dhillon AS, Kolch W. Untying the regulation of the Raf-1 kinase. Arch Biochem Biophys 2002; 404:3-9.
42. Dhillon AS, Meikle S, Yazici Z, Eulitz M, Kolch W. Regulation of Raf-1 activation and signalling by dephosphorylation. Embo J 2002; 21:64-71.
43. El Sheikh SS, Domin J, Abel P, Stamp G, Lalani el-N. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 2004; 6:846-53.
44. Lee JT Jr, Steelman LS, McCubrey JA. Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells. Int J Oncol 2005; 26:1637-44.
45. Shelton JG, Blalock WL, White ER, Steelman LS, McCubrey JA. Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. Cell Cycle 2004; 3:503-12.
46. McCubrey JA, Steelman LS, Blalock WL, Lee JT, Moye PW, Chang F, Pearce M, Shelton JG, White MK, Franklin RA, Pohnert SC. Synergistic effects of pi3k/akt on abrogation of cytokine-dependency induced by oncogenic raf. Adv Enzyme Regul 2001; 41:289-323.
47. McCubrey JA, Lee JT, Steelman LS, Blalock WL, Moye PW, Chang F, Pearce M, Shelton JG, White MK, Franklin RA, Pohnert SC. Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. Cancer Detect Prev 2001; 25:375-93.
48. Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, Moye PW, Franklin RA, Pohnert SC, Mirza AM, McMahon M, McCubrey JA. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene 2003; 22:2478-92.
49. Blalock WL, Navolanic PM, Steelman LS, Shelton JG, Moye PW, Lee JT, Franklin RA, Mirza A, McMahon M, White MK, McCubrey JA. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. Leukemia 2003; 17:1058-67.
50. Shelton JG, Steelman LS, White ER, McCubrey JA. Synergy between PI3K/Akt and Raf/MEK/ERK Pathways in IGF-1R Mediated Cell Cycle Progression and Prevention of Apoptosis in Hematopoietic Cells. Cell Cycle 2004; 3:372-9.
51. Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Franklin RA, Bertrand FE, McMahon M, McCubrey JA. Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle 2005; 4:822-30.
52. Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Bertrand FE, Franklin RA, McCubrey. Effects of endogenous epidermal growth factor receptor signaling on DNA synthesis and ERK activation in a cytokine-dependent hematopoietic cell line. Cell Cycle 2005; 4:818-21.
53. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004; 64:5232-6.
54. Ghosh PM, Malik S, Bedolla R, Kreisberg JI. Akt in prostate cancer: possible role in androgen-independence. Curr Drug Metab 2003; 4:487-96.
55. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002; 8:1168-71.
56. van Brussel JP, Mickisch GH. Multidrug resistance in prostate cancer. Onkologie, 2003; 26:175-81.
57. van Brussel JP, van Steenbrugge GJ, Romijn JC, Schroder FH, Mickisch GH. Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 1999; 35:664-71.
58. Wendel HG, Lowe SW. Reversing Drug Resistance In Vivo. Cell Cycle 2004; 3:847-9.
59. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428:332-7.